June 3, 2021 – Abbott (Abbott Park, IL) announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare ventricular assist device (HVAD).
Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott’s HeartMate 3 heart pumps to their patients.
Abbott’s HeartMate 3 heart pump is a small, implantable mechanical circulatory support device for advanced heart failure patients requiring either short- or long-term support who are awaiting a heart transplant or who are not candidates for heart transplantation.
HeartMate 3 is also approved for pediatric use.